Switching HIV Treatment: Research
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Long-Term Efficacy and Safety of Emtricitabine (FTC) in HIV-Positive Adults Switching from a Lamivudine (3TC)-Containing HAART Regimen (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Tenofovir DF: A 24-Week Interim Analysis From a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Long-Term Follow-Up of MAINTAVIR Study: Substitution of a NNRTI for Protease Inhibitor in Patients on Combination Therapy with Undetectable Plasma Viral Loads (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Clinical Experience of Amprenavir (APV) Following Nelfinavir (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
In New England Journal of Medicine
- HIV NAT 002.1/002.2: Immediate (IS) Versus Deferred Switching (DS) from ddI/D4T to AZT/3TC in an HIV+ Thai Population and Determine Predictors to Improve Treatment Response to Long-Term Dual Nucleoside Therapy as an Option for Resource-Limited Countries (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Swiss Research Finds That Switching Therapy May Not Lower High Lipid Levels (May 4, 2001)
From Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- SWATCH Study: A Multicenter Trial of Proactive Treatment Switching. Results at Nine Months of Follow-Up (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
